ArticleVaccine2024

Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older.

Shoroq M Altawalbeh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.